Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 50268-587

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 50268-587). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (16cd3370 8ddc 4dbb 82b3 98e128fb3482 01)

Chemical structure diagram of memantine hydrochloride showing the molecular framework with labeled NH2, HCl, and CH3 groups.*

FDA Label Image

Figure 1 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 02)

A line graph showing the mean change from baseline in the ADCS-ADL score over 28 weeks of treatment comparing placebo and Memantine Hydrochloride. The graph illustrates clinical improvement and decline with error bars representing SEM, indicating Memantine Hydrochloride consistently shows less clinical decline than placebo over time.*

FDA Label Image

Figure 2 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 03)

A cumulative percentage of patients line graph comparing Placebo and Memantine Hydrochloride, showing ADCS-ADL change from baseline on the x-axis and cumulative percentage of patients on the y-axis. Memantine Hydrochloride is represented by circles and Placebo by squares, with Memantine Hydrochloride showing a higher cumulative percentage across the range of ADCS-ADL changes.*

FDA Label Image

Figure 3 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 04)

A line graph depicting the mean change from baseline in SIB (Severe Impairment Battery) score over 28 weeks of treatment. It compares two groups, placebo and memantine hydrochloride, showing clinical improvement or decline over time.*

FDA Label Image

Figure 4 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 05)

A cumulative percentage graph comparing the effect of Memantine Hydrochloride versus placebo on SIB (Severe Impairment Battery) change from baseline. The graph shows the cumulative percentage of patients on the vertical axis and SIB change from baseline on the horizontal axis, illustrating a higher improvement trend for Memantine Hydrochloride over placebo.*

FDA Label Image

Figure 5 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 06)

A line graph showing the mean change from baseline in ADCS-ADL scores over 24 weeks of treatment. Two treatment groups are compared: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The graph includes data points with error bars and indicates clinical improvement and clinical decline thresholds on the y-axis.*

FDA Label Image

Figure 6 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 07)

A cumulative percentage of patients chart showing ADCS-ADL change from baseline on the x-axis and the cumulative percentage of patients on the y-axis. The graph compares two groups: Placebo/Donepezil represented by black squares, and Memantine Hydrochloride/Donepezil represented by open circles.*

FDA Label Image

Figure 7 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 08)

A line graph showing mean change from baseline in SIB score over 24 weeks of treatment comparing Placebo/Donepezil to Memantine Hydrochloride/Donepezil. The graph includes error bars representing SEM, with a horizontal line indicating clinical improvement (above) and clinical decline (below).*

FDA Label Image

Figure 8 (16cd3370 8ddc 4dbb 82b3 98e128fb3482 09)

A line graph showing cumulative percentage of patients on the vertical axis and SIB change from baseline on the horizontal axis. It compares outcomes between two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil, indicated by square and circle markers respectively.*

FDA Label Image

1 (587 13)

Label for Memantine Hydrochloride Tablets, USP, 5 mg film-coated oral tablets. The label indicates prescription use only with a package size of 30 tablets (3 x 10 unit dose). It includes dosage content, storage instructions, manufacturer information (AvPAK, Pulaski, TN), a barcode, and revision dates. The label emphasizes keeping the drug out of reach of children.*

FDA Label Image

2 (588 13)

Label for Memantine Hydrochloride Tablets, USP 10 mg film-coated tablets by AvPAK. The label indicates Rx only, with a package size of 30 tablets (3 x 10) unit dose. It includes storage instructions, a barcode, and manufacturer information for AvKARE in Pulaski, TN.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.